Abstract: Provided herein, inter alia, are compositions and methods for treating or preventing viral infections. The methods and compositions may modulate entry of a virus into a cell, viral fusion to a cell, or cell to cell spread of the virus by targeting one or more viral proteins or ligands thereof. The methods and compositions provided herein including embodiments thereof are contemplated to be especially effective for treating or preventing cytomegalovirus infections.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for distributing a top k computation across multiple computing units of an integrated circuit One of the methods includes computing, by each of the plurality of computing units and for each candidate vector in a respective subset of the candidate vectors assigned to the computing unit, a respective distance between the query vector and the candidate vector; initializing, by the integrated circuit, a cut-off distance value; determining, by the integrated circuit, a final cut-off distance value; and providing, by the integrated circuit and as an output of a top k computation for the query vector and the set of candidate vectors, the candidate vectors that have respective distances that satisfy the final cut-off distance value.

Abstract: An aerosol device having a bowl with a bottom defining a drain, and a side wall extending from the bottom to a rim. A nozzle is disposed within the bowl. The nozzle defines a chamber and an outlet orifice directed toward the side wall of the bowl. The aerosol device includes a liquid container fluidly coupled to the nozzle via a first conduit having an outlet tip disposed within the chamber of the nozzle and a second conduit connecting a source of pressurized gas to the chamber of the nozzle. The outlet tip is in the form of a tube defining elongated slots communicating from inside the tube to outside the tube, the slots each having a width defined between two parallel tube surfaces. The aerosol device generates submicron liquid droplets, and is suitable for disinfecting porous articles in an enclosed volume.

Abstract: Data formatting rules to convert data from one form to another form are automatically determined based on a user's edits. A machine learning heuristic is applied to a user's edits to determine a data formatting rule that may be applied to data. For example, a user may make edits that add/remove characters from data, concatenate data, extract data, rename data, and the like. The machine learning heuristic may be automatically triggered in response to an event (e.g. after a predetermined number of edits are made to a same type of data) or manually triggered (e.g. selecting a user interface option). The data formatting rule may be applied to other data and the results of the formatting reviewable by the user. Based on further edits/reviews, the data formatting rule may be updated. The data formatting rules may be stored for later use.

Abstract: To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.

Abstract: An aerosol device having a bowl with a bottom defining a drain, and a side wall extending from the bottom to a rim. A nozzle is disposed within the bowl. The nozzle defines a chamber and an outlet orifice directed toward the side wall of the bowl. The aerosol device includes a liquid container fluidly coupled to the nozzle via a first conduit having an outlet tip disposed within the chamber of the nozzle and a second conduit connecting a source of pressurized gas to the chamber of the nozzle. The outlet tip is in the form of a tube defining elongated slots communicating from inside the tube to outside the tube, the slots each having a width defined between two parallel tube surfaces. The aerosol device generates submicron liquid droplets, and is suitable for disinfecting porous articles in an enclosed volume.

Abstract: A composition comprising a TRAIL-R2 receptor or fragment thereof bound to a ligand in crystalline form is presently provided along with novel binding sites and binding agents of a TRAIL receptor. Also provided are methods of designing a compound, protein or peptide and identifying a binding agent that interacts with a TRAIL receptor. The present invention further provides methods of modulating binding of a TRAIL receptor to a ligand, the methods comprising contacting the TRAIL receptor with a binding agent, ligand, or an agonist or antagonist thereof, that interacts with a novel binding site described herein.

Abstract: To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.

Abstract: A composition comprising a TRAIL-R2 receptor or fragment thereof bound to a ligand in crystalline form is presently provided along with novel binding sites and binding agents of a TRAIL receptor. Also provided are methods of designing a compound, protein or peptide and identifying a binding agent that interacts with a TRAIL receptor. The present invention further provides methods of modulating binding of a TRAIL receptor to a ligand, the methods comprising contacting the TRAIL receptor with a binding agent, ligand, or an agonist or antagonist thereof, that interacts with a novel binding site described herein.

Abstract: Animation and visuals are displayed when automatically filling/changing values within a document. A scan animation may be displayed to assist a user in understanding that an action is about to occur using their recent edit(s). A fill animation may be displayed while the suggested values are automatically filled within the document. For example, the suggested values may be displayed according to an uncommitted state (e.g. light grey text) as compared to a committed state (e.g. black text) of related values. The suggested values may be accepted/rejected while they are displayed according to the uncommitted state. When the suggested values are rejected, the suggested values are removed from the display. When the suggested values are accepted, the suggested values are transitioned to the committed state. When a user performs an edit on one or more of the suggested values, a change animation may be displayed.

Abstract: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.

Abstract: Disclosed is a novel insurance product that provides an accelerated death benefit to the insured individual. The insurance product contains a lifeaccess accelerated benefit feature that allows the insured individual to file a claim and receive benefits under a life insurance product if the insured individual becomes chronically or terminally ill.

Abstract: Data formatting rules to convert data from one form to another form are automatically determined based on a user's edits. A machine learning heuristic is applied to a user's edits to determine a data formatting rule that may be applied to data. For example, a user may make edits that add/remove characters from data, concatenate data, extract data, rename data, and the like. The machine learning heuristic may be automatically triggered in response to an event (e.g. after a predetermined number of edits are made to a same type of data) or manually triggered (e.g. selecting a user interface option). The data formatting rule may be applied to other data and the results of the formatting reviewable by the user. Based on further edits/reviews, the data formatting rule may be updated. The data formatting rules may be stored for later use.

Abstract: Disclosed is a novel insurance product that provides an accelerated death benefit to the insured individual. The insurance product contains a lifeaccess accelerated benefit feature that allows the insured individual to file a claim and receive benefits under a life insurance product if the insured individual becomes chronically or terminally ill.

Abstract: A method for processing data related to a life insurance product having a death benefit amount payable to a beneficiary upon death of an insured includes receiving data indicative of certification that the insured is chronically ill, and responsive to receipt of the data indicative of the certification, providing output signals having data indicative of instructions to pay an owner of the life insurance product periodic payments, during the lifetime of the insured, each of which periodic payments reduces the death benefit amount.

Abstract: Disclosed is a novel insurance product that provides an accelerated death benefit to the insured individual. The insurance product contains a lifeaccess accelerated benefit feature that allows the insured individual to file a claim and receive benefits under a life insurance product if the insured individual becomes chronically or terminally ill.

Abstract: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.

Abstract: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.

Abstract: Disclosed is a novel insurance product that provides an accelerated death benefit to the insured individual. The insurance product contains a lifeaccess accelerated benefit feature that allows the insured individual to file a claim and receive benefits under a life insurance product if the insured individual becomes chronically or terminally ill.